Rocket One Inc. Common Stock (NASDAQ:RKTO) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) from a strong sell rating to a sell rating in a report issued on Saturday morning.

Separately, Weiss Ratings downgraded shares of Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.00.

Rocket One Inc. Common Stock Stock Performance

Shares of RKTO opened at $0.76 on Friday. The business has a 50-day moving average of $1.03 and a 200 day moving average of $0.92. Rocket One Inc. Common Stock has a fifty-two week low of $0.49 and a fifty-two week high of $2.45. The firm has a market cap of $16.96 million, a P/E ratio of -0.95 and a beta of 0.96.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03).

Institutional Trading of Rocket One Inc. Common Stock

A number of institutional investors have recently added to or reduced their stakes in the stock. Lido Advisors LLC purchased a new position in Rocket One Inc. Common Stock during the 3rd quarter valued at about $32,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Rocket One Inc. Common Stock in the third quarter worth about $51,000. Geode Capital Management LLC boosted its position in shares of Rocket One Inc. Common Stock by 8.0% in the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares during the period. Virtu Financial LLC bought a new position in shares of Rocket One Inc. Common Stock in the third quarter valued at approximately $184,000. Finally, Citadel Advisors LLC purchased a new position in Rocket One Inc. Common Stock during the third quarter valued at approximately $232,000. Hedge funds and other institutional investors own 7.08% of the company’s stock.

Rocket One Inc. Common Stock Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.